- Home
- NZF vs OGN Comparison
NZF vs OGN Comparison
Compare NZF & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- OGN
- Stock Information
- Founded
- NZF 2001
- OGN 1923
- Country
- NZF United States
- OGN United States
- Employees
- NZF N/A
- OGN N/A
- Industry
- NZF Finance Companies
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- NZF Finance
- OGN Health Care
- Exchange
- NZF Nasdaq
- OGN Nasdaq
- Market Cap
- NZF 2.3B
- OGN 2.5B
- IPO Year
- NZF N/A
- OGN N/A
- Fundamental
- Price
- NZF $11.58
- OGN $9.52
- Analyst Decision
- NZF
- OGN Hold
- Analyst Count
- NZF 0
- OGN 4
- Target Price
- NZF N/A
- OGN $18.00
- AVG Volume (30 Days)
- NZF 496.8K
- OGN 3.5M
- Earning Date
- NZF 01-01-0001
- OGN 08-05-2025
- Dividend Yield
- NZF 4.67%
- OGN 0.85%
- EPS Growth
- NZF N/A
- OGN N/A
- EPS
- NZF N/A
- OGN 2.88
- Revenue
- NZF N/A
- OGN $6,294,000,000.00
- Revenue This Year
- NZF N/A
- OGN N/A
- Revenue Next Year
- NZF N/A
- OGN $1.11
- P/E Ratio
- NZF N/A
- OGN $3.29
- Revenue Growth
- NZF N/A
- OGN N/A
- 52 Week Low
- NZF $9.82
- OGN $8.01
- 52 Week High
- NZF $12.29
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- NZF 28.48
- OGN 44.17
- Support Level
- NZF $11.72
- OGN $9.53
- Resistance Level
- NZF $12.02
- OGN $10.27
- Average True Range (ATR)
- NZF 0.07
- OGN 0.34
- MACD
- NZF -0.04
- OGN -0.04
- Stochastic Oscillator
- NZF 0.00
- OGN 5.49
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.